For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.
Price · 1Y
$35.95
Thesis
Structure Therapeutics is developing oral small-molecule GLP-1 receptor agonist candidates for obesity and metabolic conditions. As a pure-play, its prospects depend on the clinical advancement of these oral programs.
Catalysts
- Oral GLP-1 candidate clinical trial readouts
- Pipeline expansion into additional indications
- Advancement into later-stage development
Recent events
Material filings, federal awards, and regulatory activity. Impact is scored against market cap.
- Sep 8OtherSEC
Structure Therapeutics Inc. filed Form 8-K covering items 7.01, 8.01 and 9.01.
- Aug 6Financial resultsSEC
Structure Therapeutics Inc. files 8-K (items 2.02, 9.01) disclosing financial results.
- May 7Financial resultsSEC
8-K filing (items 1.01,2.02,8.01,9.01) covering material agreement and financial results.
- May 7Securities offeringSEC
Structure Therapeutics filed Form 424B5 prospectus supplement.